Adips Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 11-07-2024
- Paid Up Capital ₹ 0.98 M
as on 11-07-2024
- Company Age 24 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.50 M
as on 11-07-2024
- Revenue -21.75%
(FY 2021)
- Profit -16.28%
(FY 2021)
- Ebitda -15.60%
(FY 2021)
- Net Worth 9.00%
(FY 2021)
- Total Assets 2.66%
(FY 2021)
About Adips Laboratories
The Corporate was formerly known as Adips Laboratories Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.98 M.
The company has closed loans amounting to ₹0.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Narinder Sethi, Renu Gera, Om Gera, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239DL2000PLC105152
- Company No.
105152
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Adips Laboratories Limited offer?
Adips Laboratories Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets.
Who are the key members and board of directors at Adips Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lokendra Gera  | Whole-Time Director | 01-Aug-2002 | Current |
| Narinder Sethi | Whole-Time Director | 10-Apr-2000 | Current |
| Renu Gera | Whole-Time Director | 10-Apr-2000 | Current |
| Om Gera | Whole-Time Director | 10-Apr-2000 | Current |
Financial Performance and Corporate Structure Insights of Adips Laboratories.
Adips Laboratories Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 21.75% decrease. The company also saw a substantial fall in profitability, with a 16.28% decrease in profit. The company's net worth moved up by a moderate rise of 9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adips Laboratories?
In 2021, Adips Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punajab National Bank Creation Date: 05 Apr 2004 | ₹0.50 M | Satisfied |
How Many Employees Work at Adips Laboratories?
Adips Laboratories has a workforce of 26 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adips Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adips Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
